Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
50M
-
Number of holders
-
93
-
Total 13F shares, excl. options
-
23.8M
-
Shares change
-
-1.12M
-
Total reported value, excl. options
-
$315M
-
Value change
-
-$24.2M
-
Put/Call ratio
-
0.84
-
Number of buys
-
42
-
Number of sells
-
-48
-
Price
-
$13.23
Significant Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q4 2021
121 filings reported holding KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share as of Q4 2021.
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) has 93 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23.8M shares
of 50M outstanding shares and own 47.57% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (1.93M shares), WELLINGTON MANAGEMENT GROUP LLP (1.81M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (1.75M shares), Vivo Capital, LLC (1.53M shares), BlackRock Inc. (1.5M shares), Deep Track Capital, LP (1.5M shares), FRAZIER MANAGEMENT LLC (1.31M shares), FRANKLIN RESOURCES INC (1.25M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1.18M shares), and VANGUARD GROUP INC (1.14M shares).
This table shows the top 93 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.